CORT: Class Action Sparks 50% Decline — Act Now!

Company Background & Recent Developments

Corcept Therapeutics (NASDAQ: CORT) is a commercial-stage biopharmaceutical company focused on drugs that modulate the hormone cortisol for treating serious metabolic, oncologic, and adrenal disorders (www.biospace.com). Its flagship product Korlym (mifepristone) is approved for Cushing’s syndrome (hypercortisolism) and has driven the company’s growth. In late 2025, Corcept’s fortunes abruptly changed: on December 31, 2025 the FDA issued a Complete Response Letter (CRL) rejecting Corcept’s New Drug Application (NDA) for relacorilant (a next-generation cortisol modulator) due to insufficient evidence of efficacy (intellectia.ai) (www.globenewswire.com). This surprise regulatory setback triggered a plunge in CORT’s stock price from about $70 to $34.80 – a 50.4% collapse in a single day, erasing over $3.6 billion in market value (www.globenewswire.com). Within weeks, shareholder rights law firms announced class-action lawsuits alleging that Corcept misled investors about relacorilant’s prospects despite being warned by the FDA of “evidence gaps” prior to the NDA submission (www.globenewswire.com) (www.globenewswire.com). The stock’s dramatic decline and ensuing litigation have put Corcept under intense scrutiny, bringing both urgent challenges and potential opportunities for current and prospective investors.

Dividend Policy & Shareholder Returns

Corcept does not pay any dividend and has never returned cash to shareholders via dividends (www.sec.gov). Management explicitly states that it has “never declared or paid cash dividends” and has no plans to do so in the foreseeable future (www.sec.gov). Instead, Corcept has used share repurchases as a way to return value. Notably, in 2025 the company spent $245.9 million on buybacks under its stock repurchase program (www.biospace.com). This aggressive buyback (equivalent to roughly 7% of Corcept’s year-end market capitalization) reflected management’s prior confidence in the business. However, with shares now trading around half their prior value, those repurchases – made at an average price far above current levels – raise questions about capital allocation and timing. No dividend yield exists for CORT and, given the biotech growth focus, any near-term yield is unlikely. (AFFO/FFO metrics are not applicable here, as those are used for real estate or cash-flow focused firms; Corcept’s value proposition rests on drug revenues and pipeline success rather than distributable cash flows.)

Financial Position & Leverage

Corcept entered 2026 with a solid financial position and minimal leverage. The company generated $761.4 million in revenue in 2025 (up 13% year-on-year from $675.0 million in 2024) (www.biospace.com), driven by expanded use of Korlym for Cushing’s syndrome. Despite higher operating expenses (including R&D for new trials), Corcept remained profitable in 2025, posting net income of $99.7 million (though down from $141.2 million in 2024) (www.biospace.com). Importantly, Corcept carries no long-term debt on its balance sheet – its liabilities consist mostly of accounts payable, accrued expenses, and lease obligations, with no bank loans or bond debt outstanding (www.sec.gov). At year-end 2025, the company held a robust cash and investments balance of $532.4 million (www.biospace.com), providing a substantial cushion. This net cash position means Corcept’s leverage is effectively zero, and interest coverage is not a concern – there are no interest-bearing obligations to service. Maturity risk from debt is nonexistent. Instead, the key “maturities” on the horizon are the patent expirations and exclusivity timelines for Corcept’s drug portfolio. Until recently, Corcept had expected to protect Korlym’s market exclusivity until 2037 via patents (fintool.com); that assumption has been upended by recent legal developments (discussed below). Overall, the balance sheet strength gives Corcept some ability to weather near-term adversity, though the company’s heavy dependence on one product means cash burn could accelerate if revenues erode.

Pipeline Status and Growth Prospects

Corcept’s growth narrative has centered on expanding uses for cortisol modulators, but recent setbacks cloud these prospects. Relacorilant, a next-generation cortisol blocker intended as a successor to Korlym, was the company’s lead pipeline candidate for Cushing’s syndrome. Throughout 2024–2025, management conveyed “high confidence” that relacorilant’s clinical trial data were robust (www.globenewswire.com). However, as the new class-action alleges, the FDA had repeatedly warned Corcept during pre-submission meetings that the relacorilant data were inadequate, specifically lacking evidence of effectiveness on hypertension in Cushing’s patients (www.globenewswire.com). Corcept proceeded to file the NDA despite these warnings, only to receive a CRL on Dec. 31, 2025 confirming that the FDA “could not arrive at a favorable benefit-risk assessment” without further efficacy data (www.globenewswire.com). This development not only shattered near-term approval hopes but also undermined trust in management’s assurances. Corcept now says it is “engaged with the FDA to determine the best path forward” for relacorilant in Cushing’s and remains “confident that the ultimate outcome will be approval.” (www.biospace.com). Nevertheless, approval will clearly be delayed – likely requiring new clinical studies or data analyses – pushing any potential relacorilant launch out by years and at additional cost.

On a more positive note, Corcept has other shots on goal in its pipeline. The company already filed an NDA for relacorilant in a completely different indication – platinum-resistant ovarian cancer – based on its Phase 3 ROSELLA trial. That ovarian cancer NDA was accepted, with an FDA decision (PDUFA date) scheduled for July 11, 2026 (www.biospace.com). If approved, relacorilant could become a first-in-class therapy in a niche oncology setting, potentially diversifying Corcept’s revenue beyond Cushing’s. Additionally, Corcept is conducting multiple mid- to late-stage trials: the BELLA study in advanced ovarian cancer (results expected end of 2026), MONARCH Phase 2b in metabolic-associated fatty liver disease (MASH, results by end of 2027), and plans for a Phase 3 trial of dazucorilant (another cortisol modulator) for a psychiatric or metabolic indication (www.biospace.com). These pipeline assets underscore Corcept’s efforts to broaden its portfolio. However, none of these programs are guaranteed successes – clinical and regulatory risks remain high, and any revenue from them is years away at best. In the near term, Korlym for Cushing’s remains the economic engine, and it faces intensifying challenges.

Competitive Landscape and Patent Setback

Corcept’s Cushing’s syndrome franchise is encountering both competition and looming generic entry. Korlym has been a lucrative orphan drug for years, but alternative therapies have emerged. Recordati’s Isturisa (osilodrostat) and Xeris Biopharma’s Recorlev (levoketoconazole) are newer FDA-approved treatments for Cushing’s syndrome, providing physicians with options beyond Korlym. Corcept’s strategy to defend its turf relied partly on patents protecting specific methods of Korlym’s use. The company engaged in an extended legal battle with Teva Pharmaceutical to prevent a generic Korlym. Corcept held patents (e.g., U.S. Patents 10,195,214 and 10,842,800) covering methods for safely co-administering Korlym with CYP3A4 inhibitors (important because many Cushing’s patients take drugs like ketoconazole) (fintool.com). Initially, a federal court ruled against Corcept in late 2023, and on Feb. 19, 2026, the U.S. Court of Appeals affirmed that Teva’s generic does not infringe these patents (fintool.com). This appellate decision removed a major legal barrier to generic competition (fintool.com), effectively clearing Teva (and potentially other generic manufacturers) to launch generic mifepristone for Cushing’s once regulatory requirements are met. Corcept expressed disappointment and hinted at pursuing further review (fintool.com), but barring a highly unlikely reversal, generic Korlym could hit the market imminently. In fact, Teva first filed for FDA approval of generic Korlym back in 2018 (fintool.com), so it is presumably ready to launch. The stock market has already reacted: CORT shares tumbled ~25% on Feb. 19, 2026 when the appeals verdict was announced (fintool.com). The loss of exclusivity many years earlier than 2037 will almost certainly lead to a sharp drop in Korlym sales once generics arrive, as payers and patients shift to cheaper alternatives. This development places immense pressure on Corcept’s pipeline to replace lost revenue.

Valuation Metrics and Outlook

After these cascading setbacks, Corcept’s valuation has dramatically reset – but whether it now represents a bargain or a value trap is debatable. At the current share price near the mid-$20s to low-$30s (post-crash), Corcept’s market capitalization stands roughly around $2.5–3.5 billion (down from ~$7 billion before the CRL) (www.globenewswire.com). In 2025, the company earned $99.7 million in net income (www.biospace.com), so the trailing price-to-earnings ratio is in the range of ~25–35× depending on the exact stock price – a rich multiple for a company facing imminent revenue loss. On a sales basis, the stock trades near 3–4× trailing annual revenue, given $761 million 2025 sales (www.biospace.com). Cash on hand (~$532 million) covers a healthy chunk of the firm’s market cap, meaning enterprise value-to-sales is a bit lower, around 3.0–3.5×. For comparison, other small-cap biotechs with a single commercial product often trade at low single-digit sales multiples, especially when patent expiry looms. Corcept’s premium valuation historically was premised on growth expectations – management even issued 2026 revenue guidance of $900–$1,000 million in February (www.biospace.com). That guidance now looks very ambitious: it implied ~20–30% growth, which is hard to envision if a Korlym generic launches in mid-2026 and relacorilant for Cushing’s remains off the market. Unless the ovarian cancer indication or other pipeline assets generate significant revenue soon (which is uncertain given their clinical stage), analysts will likely slash forward earnings estimates. In sum, Corcept’s current valuation does not scream “cheap” on conventional metrics – it largely reflects hope of maintaining revenues in 2026 and beyond. If those hopes falter, the stock may have further to fall; conversely, successful navigation of these challenges (e.g. a surprise near-term resolution with the FDA or a slower generic roll-out) would be needed to justify upside.

Risks and Red Flags

Corcept’s situation comes with an array of risks and warning signs, which investors must weigh carefully:

– Regulatory and Pipeline Risk: The FDA rejection of relacorilant in Cushing’s syndrome underscores the uncertainty of drug development. Despite positive spin from management, Corcept will likely need additional trials or data to satisfy regulators (www.globenewswire.com), delaying potential approval by perhaps several years. There is no guarantee relacorilant will ever be approved for Cushing’s – the FDA’s concerns about insufficient efficacy data (specifically on blood pressure outcomes) point to a fundamental shortfall that may not be easily remedied (www.globenewswire.com). Furthermore, upcoming regulatory events like the ovarian cancer relacorilant PDUFA in July 2026 carry risk; if that application is not approved or faces delays, it would remove one of the few positive catalysts in the near term.

– Patent Cliff and Generic Competition: The adverse court ruling in favor of Teva is a major red flag for Corcept’s core business. Generic competition for Korlym could erode the company’s main revenue source rapidly, given that Korlym contributed essentially all of the $761 million in 2025 sales. Corcept may attempt strategies to defend market share (e.g., introducing its own authorized generic or leveraging patient support programs), and indeed the company had contingency plans in case of an unfavorable outcome (www.sec.gov) (www.sec.gov). However, history shows once a lower-cost generic is available, brand sales for a small-molecule drug typically plummet. The risk of significant revenue and profit decline in 2026–2027 is therefore high.

– Concentration & Competition: Corcept is highly reliant on a single therapeutic area and product. Even prior to generic entry, competition from alternate Cushing’s treatments (Isturisa, Recorlev) has been increasing (www.sec.gov). Any loss of market share – whether from new branded rivals or generics – has an outsized impact because the company does not yet have diversified income streams. This lack of diversification amplifies risk.

– Management Credibility and Legal Overhang: The allegations in the class action lawsuit suggest that management may have misled investors about relacorilant’s readiness and downplayed known FDA concerns (www.globenewswire.com) (www.globenewswire.com). If proven, this points to a serious lapse in transparency and governance. Even if the claims are not ultimately proven in court, the fact remains that management’s public statements were overly optimistic relative to reality – a red flag for investor trust. The class action itself (filed on behalf of investors who bought in late 2024–2025) will consume management attention and could result in financial penalties or a settlement (though likely covered in part by insurance). Separately, Corcept previously faced other legal issues – for example, a settlement of $14 million in 2023 related to the Melucci litigation (www.sec.gov) (www.sec.gov) – indicating a history of legal distractions. These issues raise questions about oversight and risk management within the company.

– Capital Allocation & Financial Risk: Corcept’s decision to spend nearly $246 million on share repurchases in 2025 (www.biospace.com) now appears ill-timed. Deploying cash at ~$50–60 per share (est.) only months before a catastrophic price drop could be viewed as a misallocation of capital, potentially based on unrealistic confidence in their outlook. That cash might have been better preserved to fund R&D or cushion against a downturn. Going forward, if Korlym revenues collapse, Corcept may burn cash more quickly to support its pipeline; its cash reserves, while large, are not unlimited. The company could face the need to raise capital (via equity or debt) in a couple of years if new revenue streams don’t materialize – not an immediate risk, but a medium-term concern given the changed circumstances. Any new financing under duress could be dilutive or on less favorable terms.

– External/Other Risks: Corcept also faces some unique external risks. Because mifepristone (Korlym) is the same compound used in abortion medication, political and public perception factors can indirectly impact the company. Regulatory or legislative actions restricting mifepristone distribution for pregnancy termination could complicate Korlym’s availability for Cushing’s patients (www.sec.gov). While this risk is hard to quantify, it’s a background factor to monitor. Additionally, pricing pressure in the pharmaceutical industry and potential healthcare policy changes (e.g., drug price negotiations or caps under laws like the Inflation Reduction Act) could weigh on Korlym’s profitability over time – especially as a mature product.

In sum, Corcept is navigating a perfect storm of risks: a critical pipeline setback, imminent loss of exclusivity, concentrated revenue exposure, and questions of leadership credibility. Each of these would be significant on its own; together they create a highly challenging environment.

Open Questions & What to Watch

With the stock down sharply and the company at a crossroads, several open questions will determine the path forward:

– Can Korlym’s Franchise Be Sustained at All? How quickly will a generic mifepristone enter the market, and how much of Korlym’s sales can Corcept retain? Will Corcept launch an authorized generic or cut pricing to compete, and what will that do to margins? There is also the possibility of some Cushing’s patients sticking with Korlym due to brand loyalty or complexities in switching, but the extent is uncertain. Investors should watch for any guidance from Corcept on post-generic retention or plans (e.g., volume agreements, rebates) to defend market share. Also, keep an eye on competitors Recordati and Xeris – if they aggressively push Isturisa or Recorlev on the news, Korlym could lose share even faster.

– What is the Regulatory Path Forward for Relacorilant? The company claims confidence that relacorilant will eventually be approved for Cushing’s (www.biospace.com), but how and when? Will Corcept need to run an additional Phase 3 trial (for example, focusing on hypertension endpoints that the FDA flagged)? An updated plan or meeting outcome with the FDA, if announced in coming months, will be crucial. If the FDA requires lengthy new studies, relacorilant could be 3–4+ years away from approval. On the other hand, if Corcept can find a compromise (such as a narrower indication or post-approval commitment), there might be a chance to refile sooner. The content of the redacted CRL (which was disclosed on Jan 30, 2026) (www.globenewswire.com) should be closely analyzed for clues on what exactly needs fixing. This will inform how much time and money must be invested to salvage this key program.

– Will the July 2026 Ovarian Cancer Decision Be a Lifeline? The upcoming FDA decision on relacorilant for platinum-resistant ovarian cancer is a major binary event. Approval would give Corcept a new marketed indication and potentially significant revenue in oncology (though note, ovarian cancer market is smaller and complex). It could also validate Corcept’s scientific approach and lift morale after the Cushing’s setback. Conversely, a rejection or delay would remove one of the only near-term revenue diversification opportunities. Investors should prepare for volatility around that PDUFA date. Additionally, even if approved, questions remain: how quickly can Corcept commercialize relacorilant in oncology, will oncologists adopt it readily, and might Corcept need a marketing partner for cancer? These answers will shape how much impact the approval could have.

– How Will Management and Governance Evolve? Given the class action and investor dissatisfaction, will Corcept’s board or leadership take corrective action? This could include management changes, improved disclosure practices, or a more cautious approach to guidance. So far, CEO Dr. Joseph Belanoff has been the long-time leader and public face of Corcept’s optimism (www.biospace.com) (fintool.com). If confidence in the current team erodes further, investors may call for new leadership or board refreshment. Any hints of activist investor involvement or strategic review (e.g., exploring a sale or merger) would be noteworthy. With the stock depressed, one open question is whether Corcept could become a takeover target – a larger pharmaceutical company might find value in Corcept’s cortisol modulation platform or see turnaround potential, although they would also inherit the challenges. No such moves have been announced, but it remains a possibility if the price stays low.

– What Are the Legal and Financial Outcomes of the Class Action? While shareholder lawsuits often take years to resolve, any early signals (such as other law firms filing similar suits, or a motion to dismiss by Corcept) will be of interest. If evidence shows clear-cut wrongdoing, Corcept might seek a settlement to limit protracted damage – the cost of which (perhaps insured, perhaps partially out-of-pocket) is unknown. The April 21, 2026 lead plaintiff deadline is one immediate milestone (www.globenewswire.com). Over time, the lawsuit’s progression could reveal internal documents or testimony that shape the narrative around Corcept’s conduct. Investors will want to monitor if this legal overhang results in meaningful penalties or corporate governance changes.

Conclusion

The precipitous 50% stock decline in Corcept Therapeutics – triggered by an FDA setback and compounded by a patent defeat – has thrust the company into a make-or-break juncture. “Act Now!” is an apt call to action: for existing shareholders, it may mean actively re-evaluating the investment thesis (and deciding whether to hold, sell, or even participate in legal action), and for potential investors, it means diligencing whether this fallen stock is a falling knife or a long-term opportunity. On the one hand, Corcept retains a profitable core business (for now) and a cash-rich, debt-free balance sheet (www.biospace.com) (www.sec.gov). Its expertise in cortisol modulation has produced a pipeline that could yet bear fruit – for example, a possible oncology drug approval in 2026. The current stock price already reflects a lot of bad news, and any positive surprise (such as a faster resolution with FDA or a slower-than-feared generic erosion) could drive a rebound. On the other hand, the risks are uncommonly high: the company’s primary cash cow is likely to face a steep cliff, and management’s credibility has been dented by both the FDA’s rebuke and shareholder allegations (www.globenewswire.com) (www.globenewswire.com). Essentially, Corcept is in a race against time – racing to get new products approved and launched before Korlym’s monopoly profits vanish.

For investors, caution is paramount. Key fundamentals – like the dividend policy (none) and strong cash position – remain unchanged, but the growth and earnings outlook has darkened materially. Valuation metrics around 30× earnings and ~4× sales (www.biospace.com) are not obviously cheap given the uncertainty, yet a successful turnaround could make today’s prices look attractive in hindsight. This dichotomy suggests that only those with a high risk tolerance and confidence in Corcept’s science should consider jumping in now. Others may choose to stay on the sidelines until there is clearer visibility on how management will steer through this storm. In any case, now is the time to pay close attention. Developments in the next few months – FDA meetings, the class action progress, and the July PDUFA decision – will likely determine whether CORT’s story shifts from one of crisis to one of recovery, or whether more pain is yet to come. Investors should act now by staying informed and being prepared to respond as events unfold, because in the volatile saga of Corcept Therapeutics, the stakes are suddenly as high as they’ve ever been.

Sources: Corcept 2024 10-K (www.sec.gov) (www.sec.gov); Corcept FY2025 Results (Business Wire) (www.biospace.com) (www.biospace.com); Hagens Berman press release (Feb 27, 2026) (www.globenewswire.com) (www.globenewswire.com); Bloomberg Law (news.bloomberglaw.com); Fintool News (fintool.com) (fintool.com); Class action notice (Intellectia) (intellectia.ai); Corcept PR and Investor Materials (www.biospace.com) (www.sec.gov).

For informational purposes only; not investment advice.